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a b s t r a c t
Recently, the product of equine herpesvirus type 1 (EHV-1) ORF1, a homolog to HSV-1 pUL56, was shown
to modulate MHC-I expression and innate immunity. Here, we investigated modulation of respiratory
epithelial immunity by EHV-1 pUL56 and compared responses to those of PBMCs, which are important
target cells that allow cell-associated EHV-1 viremia.
The salient observations are as follows: (i) EHV-1 signiﬁcantly down-modulated MHC-I and MHC-II
expression in equine respiratory epithelial cells (ERECs). MHC-I expression remained unaffected in
PBMCs and MHC-II expressionwas increased. (ii) Infection with an EHV-1 ORF1 deletion mutant partially
restored MHC-I and MHC-II expression and altered IFN-alpha and IL-10 mRNA expression. (iii) Deletion
of EHV-1 ORF1 also signiﬁcantly increased chemokine expression and chemotaxis of monocytes and
neutrophils in ERECs. Collectively, these results suggest a role for EHV-1 pUL56 in modulation of antigen
presentation, cytokine expression and chemotaxis at the respiratory epithelium, but not in PBMC.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Equine herpesvirus-1 (EHV-1) is a member of the Alphaherpesvir-
inae that affects horses worldwide and establishes persistent (latent)
infection in peripheral blood mononuclear cells (PBMCs) and trigem-
inal ganglia (Allen et al., 2004). The disease manifestations of EHV-1
include respiratory disease, late term abortions, neurological disease
(EHM) and chorioretinopathy in horses (Allen et al., 2004). Primary
infection occurs at the respiratory epithelium and cell-to-cell spread
results in the presence of virus in respiratory tract lymph nodes
within 12–24 h post-infection (Kydd et al., 1994). A cell-associated
viremia in PBMCs is then established, which is a prerequisite for
abortion and neurological disease (Allen et al., 2004).
Because of the ubiquitous nature of EHV-1 and the establish-
ment of lifelong latency, elimination of the pathogen from the
equine population is challenging. Currently, our approach to
controlling EHV-1 infection and disease is based on biosecurity
measures to reduce the spread between horses and vaccination.
However, while vaccines are attractive tools, immunity after
vaccination or infection is typically short-lived and incomplete,
and our ability to control EHV-1 is limited by our inability to elicit
a protective host immune response, which is a problem shared
with a number of other human and veterinary herpesviruses.
In recent years, it has become clear that protection from
herpesviruses including EHV-1 is critically dependent on the
induction of virus-speciﬁc cytotoxic T-lymphocytes (CTLs) (Allen,
2008; Kydd et al., 2003). In contrast, our understanding of the
early, innate immune responses to EHV-1 infection is lacking,
although the initial interactions between the virus and compo-
nents of the innate immune system may provide useful informa-
tion to help address the host's failure to mount protective
immunity. Possible mechanisms that may explain this failure
include the absence of efﬁcient antigen presentation, the reduc-
tion of chemoattraction of professional antigen presenting cells
(Majumder et al., 2005; Pepose, 1989), the suppression of the
interferon system (Weber and Haller, 2007), and the dysregulation
of cytokine and chemokine secretion (Soboll Hussey et al., 2011).
Because many respiratory (herpes) viruses, including EHV-1, ﬁrst
interact with the host at the level of the respiratory epithelial cell,
host/pathogen interactions at this site need to be further investigated.
It is well appreciated that epithelial cells are instrumental in the
orchestration of immune responses in mice and humans (Diamond et
al., 2000; Rate et al., 2009; Saenz et al., 2008), but the study of equine
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airway epithelia has so far been limited by the lack of suitable in vitro
models. Recently, our laboratory has established equine respiratory
epithelial cultures grown at the air ﬂuid interface (EREC) and shows
that these cultures mimic the natural airway morphologically and
immunologically (Quintana et al., 2011b). We have also demonstrated
the utility and clinical relevance of the EREC system for equine
inﬂuenza virus infection by showing that results obtained with the
model in vitro correspond well with an in vivo model (Quintana et al.,
2011a). Most recently, we showed that ERECs fully support growth and
replication of EHV-1 and respond to infection by up-regulation of TLR,
type-I interferon and pro-inﬂammatory cytokine and chemokine
expression, in addition to down-regulating MHC-I and MHC-II expres-
sion and secretion of IFN-γ (Soboll Hussey et al., 2014).
For EHV-1, a number modulatory genes have been identiﬁed
that may ultimately be responsible for the lack of long-lasting
immunity (Ambagala et al., 2004; Koppers-Lalic et al., 2005; Ma et
al., 2012; Soboll Hussey et al., 2011; Van de Walle et al., 2007,
2008, 2009). Importantly, products of two genes were identiﬁed
that interfere with MHC-I expression, which is the pre-requisite
for induction of CTL responses (Ambagala et al., 2004; Koppers-
Lalic et al., 2005; Ma et al., 2012). One of these genes is the UL49.5
protein, which has been shown to modulate MHC-1 expression by
inhibition of the transporter associated with antigen processing
(TAP) (Koppers-Lalic et al., 2005). The second is the product of the
region where the early ORF1 gene is located in the EHV-1 genome,
which encodes a protein with homology to the herpes simplex
virus 1 UL56 protein (pUL56). EHV-1 pUL56 reduced MHC-1 cell
surface expression in vitro (Ma et al., 2012) and deletion of the
ORF1/2 regions also impacts clinical disease, nasal virus shedding,
as well as IL-8 and TH-1-speciﬁc T box transcription factor (T-bet)
responses in vivo in experimentally-infected ponies (Soboll Hussey
et al., 2011).
These data are consistent with a model whereby EHV-1 pUL56
modulates respiratory epithelial immunity. Here, we address
whether pUL56 controls MHC-I and MHC-II expression, secretion
of cytokines and chemokines, and chemotaxis of neutrophils and
macrophages in the respiratory epithelium. In addition, we com-
pare viral responses of the respiratory epithelium with viral
responses in PBMCs, which are critical for transport of the virus
to secondary sites of infection and the establishment of latency.
Results
Infection and growth kinetics of parental EHV-1 and deletion mutants
in ERECs
To ensure viral growth kinetics of parental virus and EHV-1
mutants were similar and allow for a direct comparison of
immune responses to these viruses in this culture system, growth
kinetics were determined in ERECs (Fig. 1). No signiﬁcant differ-
ences were observed between the percentage of infected cells
following inoculation with the different viruses (Fig. 1a) or with
respect to extracellular (Fig. 1b) and cell-associated viral titers
(Fig. 1c). This data shows similar growth kinetics between parental
and mutant viruses.
Upregulation of TLR3 and TLR9 expression in ERECs and PBMCs
following inoculation with parental and mutant EHV-1 viruses
Modulation of TLR expression has been shown to play a role in
HSV-1 infection by altering the pro-inﬂammatory and interferon
responses as well as modulating NK cell and CTL responses
(Paludan et al., 2011; West et al., 2012). In addition, we have
previously shown that infection with EHV-1 induces expression of
TLR3 and TLR9 in the respiratory epithelium (Soboll Hussey et al.,
2014). In the current study TLR3 and TLR9 expression was
compared following infection of ERECs and PBMCs with parental
or mutant EHV-1 (Fig. 2). Inoculation with any of the viruses
signiﬁcantly up-regulated both TLR3 and TLR9 in infected ERECs
(Fig. 2a and c) and PBMCs (Fig. 2b and d). TLR3 and TLR9
expression was higher in uninfected ERECs as compared to
uninfected PBMCs. Although the upregulation of TLR3 was more
dramatic in infected ERECs than in PBMCs, upregulation of TLR9
was similar in both cell types. Finally, responses following inocu-
lation with Ab4ΔORF1 (Fig. 2) did not differ signiﬁcantly from
parental or revertant virus with respect to modulation of TLR3 or
TLR9 expression. In sum, we show similar induction
of TLR3 and TLR9 following infection with parental and mutant
Fig. 1. Growth curves of parental virus (Ab4) and mutant viruses in ERECs;
(a) mean and SEM percent infection in ERECs inoculated with Ab4 and mutants;
n¼3. (b) Mean and SEM log PFU in supernatants collected from the basolateral
chamber of ERECs inoculated with Ab4 and mutants; n¼3 horses. (c) Mean and
SEM log PFU in ERECs inoculated with Ab4 and mutants; n¼3 horses.
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viruses, but our data suggests higher expression of TLR3 in ERECs
when compared to PBMCs.
Modulation of cytokine responses following infection of ERECs or
PBMCs with parental and mutant EHV-1
Recognition of viruses by TLR3 and TLR9 typically results in
secretion of type 1 interferons as well as induction of pro-
inﬂammatory cytokine responses, as previously reported following
infection with EHV-1 (Soboll Hussey et al., 2014). Although wild
type and mutant viruses induced similar levels of TLR3 and TLR9
in EREC cultures, cytokine responses (IFN-α and IL-10) induced by
the virus lacking the ORF1 region were altered (Fig. 3). Moreover,
cytokine proﬁles differed markedly between infected ERECs and
PBMCs and a summary comparison of all cytokine responses
examined in ERECs and PBMCs is shown in Table 1. As previously
reported, infection of ERECs with Ab4 resulted in up-regulation of
type 1-interferons as well as an up-regulation of the pro-
inﬂammatory cytokines IL-1, IL-6, IL-12 and TNF-α (Table 1)
(Soboll Hussey et al., 2014). Infection with the ORF1 deletion virus
led to a signiﬁcant increase in IFN-α compared to infection with
parental Ab4 or the revertant virus (Fig. 3). In contrast, EHV-1
infection of PBMCs (i) resulted in an up-regulation of type1
interferons, albeit no differences between parental and mutant
viruses were observed, and (ii) did not result in an up-regulation
of IL-1, IL-6, or IL-12 (Table 1). Furthermore, infection of ERECs
with Ab4 resulted in signiﬁcant increases in mRNA expression of
the regulatory cytokines TGF-β and IL-10 (Table 1, Fig. 3). Deletion
of the ORF1 did not affect TGF-beta mRNA expression, but did
prevent up-regulation of IL-10 mRNA expression in ERECs (Table 1,
Fig. 3). Responses in PBMCs were different from what was
observed in ERECs in that EHV-1 infection did not affect IL-10
mRNA expression and resulted in a downregulation of TGF-β
expression, irrespective of ORF1 (Table 1). Cytokine protein ana-
lysis was also performed in sub-natants collected from the
basolateral chambers of ERECs inoculated with either parental or
mutant viruses and is shown in Table 2. IFN-γ levels in sub-natants
collected from ERECs inoculated with parental or mutant viruses
were signiﬁcantly decreased when compared to mock-inoculated
cells, but no signiﬁcant differences were observed between
mutant and parental viruses. In addition, IL-1, IL-17, IL-4, IL-10,
IFN-α and TNF-α levels were measured, but were below the
detection limit for IL-4, IL-10 and IFN-α and not signiﬁcantly
different between mock inoculated ERECs and parental or mutant
EHV-1 inoculated ERECs for IL-1, IL-17 and TNF-α (Table 2). This
data suggests differential expression of cytokines on ERECs and
PBMCs. Furthermore, while ORF1 did not appear to affect
responses of PBMCs, supression of interferon-alpha and induction
of IL-10 were observed in ERECs by EHV-1 ORF1.
Deletion of the ORF1 region in EHV-1 modulates chemokine
expression and chemotaxis in infected ERECs
Chemokines are important for (i) leukocyte trafﬁcking to the site
of infection, (ii) local immunity, and (iii) establishment of a cell
associated viremia. Their role in the establishment of a cell associated
Fig. 2. TLR3 and TLR9 expression in (a and c) ERECs, and (b and d) PBMCs collected 48 h following inoculation with Ab4 or Ab4 mutants at an MOI of 10. Different viruses
used for infections are indicated in the X-axis. Data are shown as mean and SEM percent of infected cells (black bars) or uninfected cells of the same well (white bars) that
stain positive for TLR3 (a and b) or TLR9 (c and d). nPr0.05 is where signiﬁcant differences were observed in TLR expression between media only treated ERECs or PBMCs
and cells infected with Ab4 or Ab4 mutants; n¼7.
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viremia is the facilitation of lymphocyte trafﬁcking to the infected
epithelium, which allows for virus entry into lymphocytes and
transport to secondary sites of infection. Therefore, chemokine mRNA
and protein expression in ERECs infected with parental or mutant
viruses were determined, as well as the chemotactic activities in
subnatants of infected cells. As can be seen, EHV-1 infection
increased mRNA expression of GM-CSF and IL-8 in ERECs; in contrast
GM-CSF and IL-8 expression was decreased or not altered in infected
PBMCs (Table 1). Deletion of ORF1 region prevented a signiﬁcant up-
regulation of GM-CSF mRNA expression in infected ERECs (Fig. 4a),
and also resulted in decreased GM-CSF mRNA expression in PBMC
after infection (Fig. 4b), while it had no effect on IL-8 mRNA
expression (Table 1). At the protein level, infection with parental or
revertant viruses did not result in increased IL-8 or MCP-1 secretion,
but infection with the Ab4ΔORF1 signiﬁcantly increased IL-8 and
MCP-1 (Fig. 5a). Consistent with these results, we observed signiﬁ-
cantly increased chemotaxis of neutrophils and monocytes towards
sub-natants collected from Ab4ΔORF1-inoculated ERECs when com-
pared to sub-natants collected from ERECs inoculated with parental
or revertant viruses (Fig. 5b). These data suggest that pUL56
suppresses secretion of MCP-1 and IL-8. The results of this set of
experiments suggest that pUL56 induces GM-SCF in ERECs and
counteracts supression of GM-CSF in PBMCs. Moreover, our ﬁndings
indicate that pUL56 suppresses secretion of MCP-1 and IL-8 in ERECs
as well as chemotaxis of neutrophils and monocytes towards sub-
natants of ERECs following infection.
Fig. 3. Interferon-alpha and IL-10 mRNA expression at 24 hpi of ERECs measured
by real-time PCR; white bars represent media only treatment, black bars represent
Ab4 inoculation, gray bars represent inoculation with Ab4ΔORF1, and hatched bars
represent inoculation with the Ab4ΔORF1 revertant; n¼6 for all groups. Signiﬁcant
differences from mock (media) inoculated cells are indicated by n, and signiﬁcant
differences from cells inoculated with Ab4ΔORF1 are indicated by þ; pr0.05. This
data suggests supression of interferon-alpha and induction of IL-10 in ERECs by
EHV-1 ORF1.
Table 1
Cytokine/chemokine mRNA expression in ERECs and PBMCs. Cells were collected 24 hpi with parental or mutant viruses and average cytokine/chemokine mRNA fold
changes compared to mock infected cells were determined using real-time PCR.
Cytokine/chemokine mRNA expression in ERECs Cytokine/chemokine mRNA expression in PBMCs
Mock Ab4 Ab4 ORF1Δ ORF1Rev Mock Ab4 Ab4 ORF1Δ ORF1Rev
IL-1 2 58n 118n 56n 2 0 0 1
IFN-alpha 1þ 65n,þ 276n 115n,þ 1 8n 16n 11n
IFN-beta 1 35n 224n 84n 1 168n 606n 231n
IL-6 2 6n 7n 7n 0 3 1 2
IL-12 4 12n 21n 13 1 0 0 2
TNF-alpha 1 3n 3n 4n 1 4n 5n 7n
TGF-beta 1 2n 2n 2n 2 1n 0n 1n
IL-10 1 17n,þ 0 13n,þ 9 4 1 5
GM-CSF 1 4n,þ 1 4n,þ 3þ 3þ 1n 3þ
IL-8 2 22n 19n 28n 1.3 0.3n 0.1n 0.5n
MCP-1 2 4 2 5 2 0 0 0
n¼6, Differences are considered signiﬁcant at Po0.05.
n Statistically signiﬁcant change in fold mRNA expression compared to mock infected cells.
þ Signiﬁcant differences in fold mRNA expression compared to cells inoculated with Ab4ΔORF1.
Table 2
Cytokine protein secretion into the basolateral sub-natant of the transwell growing
ERECs. Cells were collected 72 hpi with parental or mutant viruses, and cytokine/
chemokine fold changes compared to mock inoculated cells were determined by
ELISA or luminex.
Cytokine protein production fold increase compared to MOCK
infected ERECs
Ab4 ORF1Δ ORF1Rev
IL-1 1 1 1
IFN-alpha odl odl odl
TNF-alpha 1 1 1
IL-17 1 1 1
IL-4 odl odl odl
IFN-gamma 4n 6n 5n
IL-10 odl odl odl
odl indicates protein levels below the detection limit; n¼6; differences are
considered signiﬁcant at Po0.05.
n A statistically signiﬁcant change in cytokines contained in the sub-natant
compared to sub-natants from mock inoculated wells.
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Presence of ORF1 is required for maximal suppression of MHC-I and
MHC-II expression in ERECs induced by EHV-1 infection
Because of the importance of antigen presentation for induction
of adaptive immunity and because previous data suggested a
function of EHV-1 pUL56 in MHC-I expression (Ma et al., 2012), the
ﬁnal objective of our study was to investigate MHC-I and II expres-
sion in ERECs and PBMCs following infection with parental and
mutant viruses. As reported previously (Soboll Hussey et al., 2014),
infection of ERECs with Ab4 signiﬁcantly decreased MHC-I expres-
sion in infected cells when compared to mock-infected cells (Fig. 6a
and c). However, this down-modulation was partially reversed when
cells were infected with Ab4 unable to express pUL56 (Ab4ΔORF1)
(Fig. 6a and c). Furthermore, MHC-I expression in uninfected cells
from the same well remained unaffected (Fig. 6a and e). In contrast,
MHC-I expression in PBMCs was not affected by infectionwith EHV-1
irrespective of ORF1 (Fig. 6b, d, and f). In addition, MHC-II expression
was signiﬁcantly decreased in both infected and uninfected cells
(from the same wells) inoculated with Ab4 or mutant viruses when
compared to mock-infected cells (Fig. 7a, c, and e). As with MHC-I,
the lack of suppressionwith the ORF1-negative virus was only partial
(but statistically signiﬁcant). Moreover, in contrast to MHC-II expres-
sion in ERECs, MHC-II expression was signiﬁcantly increased by
parental and mutant viruses in PBMCs (Fig. 7b, d, and e). In this
case, MHC-II up-regulation was limited to infected PBMCs; expres-
sion in un-infected bystanders was not signiﬁcantly altered (Fig. 7b).
This data suggests that pUL56 participates in down-modulating
MHC-I in ERECs but not in PBMCs and that this modulation occurs
only in the context of infection. In addition, it appears that pUL56
may also participate in down-modulating MHC-II in ERECs but not in
PBMCs and that this modulation occurs in both infected and
uninfected cells from the same well.
Discussion
Immunomodulation is central to herpesvirus pathogenesis, and
likely explains the short-lived immunity observed following most
herpes virus infections. A diverse array of immune evasion
strategies, targeting both innate and adaptive immune responses
has been described for most alphaherpesviruses including EHV-1
(van der Meulen et al., 2006b). Here, we show evidence that
pUL56 (encoded by EHV-1 ORF1) modulates early innate immune
function of primary respiratory epithelial cells by targeting a
number of important immune mechanisms that have the potential
to affect induction of downstream immune responses and spread
of the virus via infected PBMCs.
Members of the pUL56 family in the Alphaherpesvirinae are
early tail-anchored membrane proteins with predominant locali-
zation in the Golgi (Koshizuka et al., 2005; Ma et al., 2012). Initial
studies investigating the role of the pUL56 in HSV-1 and HSV-2
Fig. 4. GM-CSF mRNA expression at 24 hpi of (a) ERECs, or (b) PBMCs measured by
real-time PCR; white bars represent media only treatment, black bars represent
Ab4 inoculation, gray bars represent inoculation with Ab4ΔORF1, and hatched bars
represent inoculation with the Ab4ΔORF1 revertant; n¼6 for all groups. Signiﬁcant
differences from mock (media) inoculated cells are indicated by n; pr0.05.
Fig. 5. (a) Chemokine production and (b) chemotaxis of monocytes and neutro-
phils in response to co-culture with supernatants collected from the basolateral
chamber of mock inoculated ERECs (white bars), ERECs inoculated with Ab4 (black
bars), ERECs inoculated with Ab4ΔORF1 (gray bars) or inoculated with Ab4ΔOR-
F1Rev (hatched bars) for 72 h; n¼6; signiﬁcant differences from mock (media)
inoculated cells are indicated by n, and signiﬁcant differences from cells inoculated
with Ab4ΔORF1 are indicated by þ; pr0.05.
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Fig. 6. MHC-I expression in (a, c, and e) ERECs, or (b, d, and f) PBMCs at 48 h following inoculation with Ab4 or Ab4 mutants at an MOI of 10. (a and b) Different viruses used
for infections are indicated in the X-axis. Data is shown as meanþSEM percent of infected cells (black bars) or uninfected cells in the same treatment well (white bars) that
stain positive for MHC-I. Signiﬁcant differences from mock (media) inoculated cells are indicated by n, signiﬁcant differences from cells inoculated with the Ab4ΔORF1 are
indicated by þ for infected cells, and a statistical comparison between groups in uninfected cells showed no statistical differences between groups; pr0.05. (c–f)
Representative histograms are shown for MHC-I expression in (c) infected ERECs, (d) infected PBMCs, (e) uninfected ERECs from the same treatment well, and (f) uninfected
PBMCs from the same treatment well. In histograms different colored lines indicate different treatment groups: isotype control – light gray lines, mock – gray lines, Ab4 – red
lines, Ab4ΔORF1Rev – light red lines, and Ab4ΔORF1 – black lines.
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showed that the proteins are non-essential for in vitro replication;
studies in mice suggest an important role for pUL56 in viral
pathogenesis (Berkowitz et al., 1994; Kehm et al., 1996). Our previous
studies are consistent with an important role for pUL56 in viral
pathogenesis in that the ORF1 (UL56) deletion mutant was attenu-
ated as evidenced by reduced disease symptoms and viral shedding
Fig. 7. MHC-II expression in (a, c, and e) ERECs, or (b, d, and f) PBMCs at 48 h following inoculation with Ab4 or Ab4 mutants at an MOI of 10. (a and b) Different viruses used
for infections are indicated in the X-axis. Data is shown as meanþSEM percent of infected cells (black bars) or uninfected cells in the same treatment well (white bars) that
stain positive for MHC-II (a and b). Signiﬁcant differences from mock (media) inoculated cells are indicated by n, signiﬁcant differences from cells inoculated with the
Ab4ΔORF1 are indicated by þ for infected cells and # for uninfected cells; pr0.05. (c–f) Representative histograms are shown for MHC-II expression in (c) infected ERECs,
(d) infected PBMCs, (e) uninfected ERECs from the same treatment well, and (f) uninfected PBMCs from the same treatment well. In histograms different colored lines
indicate different treatment groups: isotype control – light gray lines, mock – gray lines, Ab4 – red lines, Ab4ΔORF1Rev – light red lines, and Ab4ΔORF1 – black lines.
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in ponies (Soboll Hussey et al., 2011). Furthermore, while initial
studies investigating the function of the HSV-2 pUL56 suggested a
possible role in vesicular trafﬁcking (Koshizuka et al., 2002, 2005),
recent studies investigating the function of this protein for EHV-1
and EHV-4 infection in vitro, showed that this protein plays a role in
the regulation of MHC-I expression (Ma et al., 2012; Said et al., 2012).
Additionally, our laboratory demonstrated that EHV-1 ORF1 func-
tions in modulation of cytokine responses in vivo (Soboll Hussey
et al., 2011).
The current study conﬁrms a likely role of the EHV-1 pUL56
gene in MHC-I modulation in equine respiratory epithelial cells.
Furthermore we showed that this modulation only occurred in the
context of direct infection and did not affect uninfected cells
present in the same well, a ﬁnding indicating that presence of
virus within the cell is required for the effect on MHC-I presenta-
tion. Interestingly, our study also demonstrated that modulation of
MHC-I expression could only be observed in respiratory epithelial
cells, and conﬁrms earlier ﬁndings showing MHC-I expression in
equine PBMCs remains unaffected following infection of ponies
(Soboll Hussey et al., 2011). A cell type-speciﬁc modulation of
MHC-I expression is further supported by studies showing cell
type-speciﬁc regulation of MHC-I expression in the case of
pseudorabies virus and HSV-1 infections (Deruelle et al., 2009;
Mikloska et al., 2001).
While there has been a lot of interest in MHC-I modulation in
the context of herpesviral infection in the past because of the
importance for induction of CTL responses, other aspects of the
immune response may be equally important for induction of
persistent and protective immunity. These include cytokine pro-
duction and antigen presentation in the context of MHC-II for
induction of CD4 T-cell responses (Trgovcich et al., 2002). Our data
suggests that EHV-1 pUL56 may also alter MHC-II expression in
respiratory epithelial cells, which was observed in both infected
and uninfected ERECs collected from the same well. However,
differences in MHC-II expression between the EHV-1 pUL56
mutant and wild-type infected cells were subtle. While there are
reports suggesting, that even subtle differences in MHC-II/peptide
density can alter the nature of immune responses (DiMolfetto et
al., 1998; Pisapia et al., 2012), this was not examined in our study.
The observed effect of pUL56 on MHC-II expression was consistent
but minimal in our experiments. Because, antigen presentation via
MHC-II and initiation of immune responses depend on additional
factors including afﬁnity and availability of peptide, expression of
co-stimulatory molecules, and the microenvironment, none of
which were examined in the present study; no conclusion on
the biological relevance of pUL56 for MHC-II expression can be
drawn based on the current data. Nevertheless, of interest is the
observation that modulation of MHC-II occurred in both infected
and uninfected cells from the same well. This is in contrast to our
ﬁndings for MHC-I modulation, which occurred only in infected
cells, and implies that modulation of MHC-II may be an indirect
effect that may be mediated via a secreted factor.
Candidates for the observed MHC-II modulation include IL-10,
which has the ability to down-regulate MHC-II expression via
endocytosis and recycling (Koppelman et al., 1997; McBride et al.,
2002). Evasion of immune responses via modulation of IL-10,
either by expressing viral homologs of IL-10 or by activation of
host IL-10, has been described for a number of herpesviruses
(Redpath et al., 1999; Spencer et al., 2002). While most studies
describing viral modulation of IL-10 were on gammaherpesviruses,
EHV-1 has recently been described to modulate IL-10 responses of
PBMCs following in vitro infection (Wagner et al., 2011). In the
present study, we found an inverse correlation between IL-10
mRNA expression and MHC-II expression. Infection of ERECs with
parental and revertant viruses caused a signiﬁcant up-regulation
of IL-10 mRNA expression and concomitant down-modulation of
MHC-II. Infection of ERECs with the ORF1 deletion mutant abol-
ished the induction of IL-10 mRNA expression and partially
restored MHC-II expression. Both IL-10 mRNA and MHC-II expres-
sion differed in PBMCs, where infection resulted in signiﬁcant
increases of MHC-II expression and no signiﬁcant effect of infec-
tion on IL-10 mRNA expression, independent of the presence or
absence of the ORF1 gene in the infecting virus.
Other possible mediators targeted by EHV-1 that have the
ability to modulate MHC-II expression include the interferons.
In particular, a role of IFN-γ has been described previously for the
induction of MHC-II expression on cells that do not constitutively
express MHC-II, including epithelial cells (Abendroth et al., 2000;
Wiertz et al., 2007). We have recently shown a reduction in IFN-γ
secretion of epithelial cells following infection with EHV-1 (Soboll
Hussey et al., 2014), and this observation was conﬁrmed in the
current study. However, deletion of the ORF1 region did not
signiﬁcantly affect IFN-γ secretion by epithelial cells when com-
pared to infection with parental or revertant EHV-1, while MHC-II
expression was partially restored following infection of ERECs with
Ab4ORF1Δ. Finally, there is some evidence of IFN-α affecting MHC-
II expression when Stat2 function is impaired indicating that type-
1 interferons can affect MHC-II expression (Zhao et al., 2007). The
present study found signiﬁcant increases in IFN-α secretion of
epithelial cells as a result of ORF1 deletion. Clearly, the exact
mechanism and biological relevance of pUL56 in MHC-II modula-
tion need to be investigated further. Modulation of IL-10, IFN-α
and/or IFN-γ responses could provide explanations, but future
studies will have to investigate the relationship between the
modulation of cytokine responses and MHC-II expression at the
epithelium in more detail.
In addition to a function in modulation of MHC expression, our
data suggest that EHV-1 pUL56 interfered with GM-CSF, IL-8 and
MCP-1 production and chemotaxis of neutrophils and monocytes
following infection of ERECs. While modulation of chemotaxis and
chemokine secretion has previously been observed following
infection of a number of cell lines, in murine studies and in ERECs,
this phenomenon has previously been attributed to the function of
the EHV-1 glycoprotein G, a viral chemokine binding protein
(Thormann et al., 2012; Van de Walle et al., 2007, 2008), (Soboll
Hussey et al., 2014). The present study demonstrates that infection
with an ORF1 deletion mutant resulted in signiﬁcantly increased
levels of IL-8 and MCP-1 and increased chemotaxis of neutrophils
and monocytes when compared to infection with parental and
revertant viruses. This effect of EHV-1 ORF1 could only be
observed for IL-8 and MCP-1 at the protein level however, while
responses of mRNA expression 24 h after infection were not
signiﬁcantly different from those after infection with parental or
revertant viruses. The lack of differences at the mRNA level may
indicate that pUL56 targets IL-8 and MCP-1 secretion post-tran-
scriptionally, or may simply be dependent on the time point
chosen for mRNA analysis. As the respective proteins are likely
more stable than mRNA, the 72 h levels may reﬂect an accumula-
tion of protein over this period. At the same time, chemokine
mRNA levels can change rapidly in response to EHV-1 (Wimer
et al., 2011) and a single collection point may not have been
representative enough to measure chemokine mRNA responses.
The identiﬁcation of a possible role of the EHV-1 pUL56 on
chemokine secretion and chemotaxis is nevertheless intriguing
because of the previously reported differences between EHV-1
strains Ohio '03 and RacL11 with respect to the modulation of
chemotaxis (Thormann et al., 2012). A study by Thormann et al.
(2012) investigated the role of the EHV-1 and EHV-4 glycoprotein
G in chemotaxis and speculated that an observed strain variation
in chemotaxis modulation by EHV-1 strains Racl11 and Ohio '03,
that was independent of EHV-1 gG, may have been caused by
additional immunomodulatory factors. It is very conceivable that
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the lack of a functional ORF1 and ORF2 region, recently described
for the RacL11 strain (Ma et al., 2012; Soboll Hussey et al., 2011),
may have been contributing to the differences described between
viral strains in that study and their data are supported by the
current study. Further support for the notion that EHV-1 pUL56
plays a role in chemokine and cytokine modulation comes from
in vivo data obtained by our laboratory. We were able to demon-
strate a role for EHV-1's ORF1/2 products in modulation of IL-8
expression in PBMCs collected following infection of ponies with
parental virus or an ORF1/2 deletion mutant virus (Soboll Hussey
et al., 2011).
From the above, it is clear that differences in response to EHV-1
infection were observed between ERECs and PBMCs for a number
of immune parameters examined. These included infection rate as
well as levels of expression of TLR, cytokines and chemokines, and
MHC-I and MHC-II. Furthermore, while a number of possible
modulatory effects of EHV-1 pUL56 were identiﬁed in ERECs, the
protein did not signiﬁcantly modulate responses of PBMCs. These
differences are likely a result of the different tasks the two cell
types perform in EHV-1 pathogenesis. It is not completely clear to
what extent lytic infection with EHV-1 occurs in PBMCs, but there
is evidence of restricted late EHV-1 protein expression following
in vitro and in vivo infection of PBMC present in the upper
respiratory tract (Gryspeerdt et al., 2012). Additionally, a lack of
late viral envelope protein expression has been shown in 98% of
infected PBMCs during viremia (van der Meulen et al., 2006a) and
these mechanisms combined with incomplete lytic replication in
PBMCs are likely further viral mechanisms that help in evasion of
immune surveillance.
In conclusion, the current study highlighted cell type-speciﬁc
differences in primary cells critical for EHV-1 pathogenesis, using a
unique primary equine epithelial cell system that closely mimics
in vivo conditions of primary infection. In addition, a number of
different ways in which deletion of the EHV-1 ORF1 region alters
the host defense upon initial infection of the respiratory epithe-
lium were demonstrated. This modulation of antigen presentation,
chemotaxis and the cytokine environment at the initial host–virus
interface is likely to affect the immediate defense, as well as to
modulate further downstream stimulation of dendritic cells and
induction of adaptive immunity, as has been described for other
herpesviruses (Novak and Peng, 2005; Wiertz et al., 2007).
Material and methods
Animals and epithelial tissue collection
Upper tracheas were collected from horses at 3–15 years of age
without clinical signs of respiratory disease and immediately
following euthanasia. The horses were euthanized with an over-
dose of 0.22 mL/kg of a 39 mg/mL sodium pentobarbital solution
as previously described (Quintana et al., 2011b). Upper tracheal
rings were collected in cold Dulbecco's modiﬁed Eagle's medium
supplemented with Ham's F12 nutrient mixture (DMEM/F12)
(Mediatech Inc, Manassas, VA) for further processing. Procedures
and protocols followed the animal care guidelines of the Animal
Care and Use Committee, Colorado State University.
Isolation and culture of primary equine respiratory epithelial cells and
PBMCs
Isolation and culture of primary respiratory epithelial cells
were performed using a previously developed protocol (Quintana
et al., 2011b). Brieﬂy, tissues were washed in PBS to remove red
blood cells. Following enzymatic digestion in 1.4% pronase (Roche
Applied Science, Indianapolis, IN) and 0.1% deoxyribonuclease I
(Sigma-Aldrich, St. Louis, MO), epithelial cells were harvested
using gentle agitation in calcium and magnesium free minimal
essential medium (MEM) for 48 h. Epithelial cells were then
incubated in a plastic Petri dish for two hours to reduce ﬁbroblast
contamination by adherence. Isolated ERECs were stored in liquid
nitrogen at a concentration of 2106 cells/mL until further use.
For culture at the air–ﬂuid interface, primary ERECs were seeded
into type IV collagen (Sigma-Aldrich)-coated transwell cell culture
wells (Costar, Corning, Fisher Scientiﬁc, Fair Lawn, NJ) in DMEM/
F12, containing 2% Ultroser G (Pall Life Sciences, Pall Corp., Cergy,
France), 1% penicillin–streptomycin (Gibco, Invitrogen, Carlsbad,
CA) and 0.5% amphotericin B (Biowhittaker, Walkersville, MD).
ERECs were incubated at 37 1C and 5% CO2 atmosphere in a
humidiﬁed incubator for 3–4 weeks until they were fully differ-
entiated as determined by lack of media seepage through the
membrane of the transwell, development of a pseudostratiﬁed
epithelium, presence of cilia and secretion of mucus. PBMCs were
isolated from heparinized blood using density gradient centrifuga-
tion over Histopaque-1077 (Sigma, St. Louis, MO) as previously
described (Soboll Hussey et al., 2011).
Viruses
An early passage from the neuropathogenic EHV-1 strain Ab4,
which is known to cause respiratory disease, abortions and
neurological disease (Crowhurst et al., 1981), was used as the
parental virus. In addition, an EHV-1 Ab4 recombinant virus
lacking ORF1 (Ab4ΔORF1) and its respective revertant (Ab4ΔOR-
F1Rev) with or without the enhanced green ﬂuorescent protein
(eGFP) gene were generated from the parental virus (Goodman et
al., 2007; Ma et al., 2012). All viruses were propagated in equine
dermal cells (ATCC CCL57) and titers were established in MDBK
cells or RK13 cells, as previously described (Soboll Hussey et al.,
2011).
Growth kinetics of Ab4 or Ab4 mutants in ERECs
For the establishment of viral kinetics in ERECs, fully differ-
entiated ERECs from three horses were inoculated with parental
Ab4 (Ab4), the Ab4ΔORF1 deletion mutant or the Ab4ΔORF1
revertant (Ab4ΔORF1Rev) at an MOI of 10. The media from the
basolateral chamber of the transwell, referred to as sub-natants,
and ERECS were collected as at the times indicated on the X-axis of
the growth curves (Fig. 1). Brieﬂy, ERECs were washed with
DMEM/F12 to remove mucin before inoculation with the respec-
tive viruses or treatment with DMEM/F12 (negative control). After
a 2-h adsorption period, the inoculum was removed and replaced
with fresh maintenance medium. For determination of viral titers,
sub-natants were collected from the basolateral chamber and
stored at 80 1C until further processing. For collection of cells,
300 ml of StemPro Accutase Reagent (Gibco, Invitrogen, Carlsbad,
CA) was added to the transwell and incubated at 37 1C for
30–45 min before transfer of the cells into cryovials. The collected
cells were either stored at 80 1C until further processing, or
processed immediately for ﬂow cytometry. For determination of
viral titers in collected sub-natants and cells, standard plaque
assays were performed in RK13 cells as previously described
(Soboll Hussey et al., 2011). In addition, the percentage of infection
in ERECs was evaluated via Flow cytometry using polyclonal anti-
EHV-1 antisera (VMRD, Pullman, WA) and the CyAn™ ADP -
Multiparameter Flow Cytometer (Dako Corporation, Fort Collins,
CO). For analysis, the negative gate was set on uninfected cells
incubated with anti-EHV-1 antibody and used to subtract back-
ground ﬂuorescence.
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TLR3, TLR9, MHC-I and MHC-II ﬂow cytometry analysis
For measurement of TLR3 and TLR9 expression, fully differen-
tiated epithelial cells or freshly isolated PBMCs were inoculated at
an MOI of 10 with the eGFP-expressing recombinant viruses
Ab4eGFP Ab4ΔORF1eGFP, Ab4ΔORF1ReveGFP, or treated with
DMEM/F12 (negative control) as described above. Forty eight
hours post-inoculation (hpi), cells were collected for intracellular
staining with mouse anti-human TLR3 or TLR9, conjugated with
Alexa-Fluor 647 (Imgenex, San Diego, CA). Following collection,
cells were washed, ﬁxed in 2% Formalin and permeabilized using
1% Saponin before re-suspending the cells in 50 ml of either a
mouse anti-human TLR3 or TLR9 antibody and incubated for 2 h at
room temperature as previously described (Quintana et al., 2011b).
For measurement of MHC-I and MHC-II surface expression, cells
were transferred into a 96-well U-bottom plate, washed and
incubated with 100 ml of mouse anti-equine MHC-I and MHC-II
(CVS 22 and CVS 10) monoclonal antibodies (Lunn et al., 1996) for
45 min at 4 1C. After washing, the cells were incubated with a goat
anti-mouse antibody (Jackson Laboratories, West Grove, PA) con-
jugated with allophycocyanin (APC) (0.1 μg/mL) for 30 min at room
temperature. Cells stained for TLR3, 9, MHC-I, or MHC-II were
washed, re-suspended in FACS buffer (PBS, 0.4% FBS, 0.1% NaN3)
and analyzed using the CyAn™ ADP – Multiparameter Flow
Cytometer (Dako Corporation, Fort Collins, CO). For analysis of
results, cells were separated into infected and uninfected popula-
tions based on eGFP expression using the FITC channel. Subse-
quently, TLR expression or MHC expression was evaluated
separately in infected and uninfected cells for each treatment
group using the APC channel.
Cytokine/chemokine mRNA analysis
Cytokines and chemokines previously shown to be modulated
by infection with EHV-1 were studied (Soboll Hussey et al., 2014).
These cytokines included IFN-α, IFN-β, IL-1, TGF-β, IL-10, GM-CSF,
IL-8 and MCP-1. RNA from ERECs inoculated with Ab4, Ab4ΔORF1
or Ab4ΔORF1Rev at an MOI of 10, or treated with DMEM/F12
(negative control) was isolated at 24 hpi by adding 1 mL TRIzol
directly onto the transwell insert. RNA was extracted using a
Qiagen RNeasy Minikit (Qiagen, Hilden, Germany) and included
treatment with deoxyribonuclease (Sigma-Aldrich, St. Louis, MO)
following the manufacturers' instructions. Reverse transcriptase
PCR (RT-PCR) of 1 μg of RNA was performed using the iScript™
cDNA synthesis kit (Bio Rad, Hercules, CA), as previously described
(Quintana et al., 2011b). Cytokine/chemokine analysis was per-
formed using previously established real-time PCR assays (http://
www.ca.uky.edu/Gluck/HorohovDW_EIRClonedCytokines.asp). A
standard housekeeping gene (β-gus) was used as an internal
control (Soboll Hussey et al., 2011). Relative expression of each
gene was determined by calculating the 2(-Delta Delta C(T)) values
using average delta CT values of EREC-AFIs treated with media
alone as calibrators (Livak and Schmittgen, 2001).
Luminex and ELISA analysis for secreted cytokines and chemokines
Sub-natants from cells infected with the various viruses
(MOI¼10) were collected from the basolateral chambers of ERECs
at 72 hpi and tested for the presence of IL-4, IL-10 and IFN-α, IL-17
and IFN-γ with a ﬂuorescent bead-based system (Luminex IS 100
instrument, Luminex Corp., http://www.luminexcorp.com) as pre-
viously described (Wagner and Freer, 2009). The data were
reported as median ﬂuorescence intensities. For standard curve
ﬁtting and calculation of concentrations in samples, the logistic 5p
formula (y¼aþb/(1þ(x/c)d)f) was used (Luminex 100 Integrated
System 2.3). In addition, IL-1 and TNF-α, IL-8 and MCP-1 in
sub-natants were measured using commercially available ELISA
kits for IL-1 (Kingﬁsher Biotech, St. Paul, MN), TNF-α (R&D systems,
Minneapolis, MN), and IL-8 (Uscn, Wuhan, China), and MCP-1
(Kingﬁsher Biotech, St. Paul, MN) according to manufacturers'
instructions.
Monocyte and neutrophil chemotaxis assays
Sub-natants were collected as described above at 72 hpi and
tested for their ability to attract monocytes and neutrophils as
previously described (Van de Walle et al., 2007; Soboll Hussey
et al., 2014). Brieﬂy, equine monocytes were isolated from hepar-
inized blood using density gradient centrifugation over
Histopaque-1077 (Sigma, St. Louis, MO), followed by separation
of adherent from non-adherent cells and collection of the adher-
ent cell population. Equine neutrophils were isolated using Percoll
gradient centrifugation (Sigma, St. Louis, MO), as previously
described (Van de Walle et al., 2007). Purity of monocyte and
neutrophil populations was conﬁrmed using cytospins and mod-
iﬁed Wright staining (Sigma-Aldrich). For chemotaxis of mono-
cytes, 300 μl of EREC sub-natants or 250 ng/mL of MCP-1 or media
alone were placed in the lower chamber of 12-well transwell
plates with a 5 μm pore size (Corning, Fisher, Pittsburgh, PA),
before adding 10,000 monocytes to the upper chamber. After
incubation at 37 1C for 2 h, the upper chamber was removed and
cells in the lower chamber were counted and expressed as total
percentage of monocytes added to the assay. For chemotaxis of
neutrophils, 600 μl of EREC sub-natants or 200 ng/mL of IL-8 or
media alone were placed in the lower chamber of 12-well
transwell plates at 3 μm pore size (Corning, Fisher, Pittsburgh,
PA), before adding 10,000 neutrophils to the upper chamber. After
incubation at 37 1C for 45 min, the upper chamber was discarded
and cells in the lower chamber were counted and expressed as
total percentage of neutrophils added to the assay.
Statistical analysis
The sample size for each experiment was determined using
data from representative experiments for power analysis at Russ
Lenth's power analysis website at Iowa State University (http://
homepage.stat.uiowa.edu/rlenth/Power/). Statistical differences
in TLR expression, cytokine and chemokine secretion, expression
of MHC-I and MHC-II, and chemotaxis of immune cells between
different treatments were analyzed by randomized block design.
Differences were considered signiﬁcant when Pr0.05.
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